S
Samantha Pozzi
Researcher at University of Modena and Reggio Emilia
Publications - 114
Citations - 3458
Samantha Pozzi is an academic researcher from University of Modena and Reggio Emilia. The author has contributed to research in topics: Lenalidomide & Bortezomib. The author has an hindex of 30, co-authored 109 publications receiving 3124 citations. Previous affiliations of Samantha Pozzi include Harvard University.
Papers
More filters
Journal ArticleDOI
ABVD Compared With BEACOPP Compared With CEC for the Initial Treatment of Patients With Advanced Hodgkin's Lymphoma: Results From the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial
Massimo Federico,Stefano Luminari,Emilio Iannitto,Giuseppe Polimeno,Luigi Marcheselli,Antonella Montanini,Antonio La Sala,Francesco Merli,Caterina Stelitano,Samantha Pozzi,Renato Scalone,Nicola Di Renzo,Pellegrino Musto,Luca Baldini,Giulia Cervetti,Francesco Angrilli,Patrizio Mazza,Maura Brugiatelli,Paolo G. Gobbi +18 more
TL;DR: BEACOPP is associated with a significantly improved PFS compared with ABVD, with a predictable higher acute toxicity, and was associated with higher rates of severe infections than ABVD and CEC.
Journal ArticleDOI
Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease
Sonia Vallet,Siddhartha Mukherjee,Siddhartha Mukherjee,Nileshwari Vaghela,Teru Hideshima,Mariateresa Fulciniti,Mariateresa Fulciniti,Samantha Pozzi,Loredana Santo,Diana Cirstea,Kishan Patel,Aliyah R. Sohani,A.R. Guimaraes,Wanling Xie,Dharminder Chauhan,Jesse Schoonmaker,Eyal C. Attar,Michael Churchill,Edie Weller,Nikhil C. Munshi,Nikhil C. Munshi,Jasbir Seehra,Ralph Weissleder,Kenneth C. Anderson,David T. Scadden,Noopur Raje +25 more
TL;DR: Targeting activin A by a soluble decoy receptor reversed osteoblast inhibition, ameliorated MM bone disease, and inhibited tumor growth in an in vivo humanized MM model, setting the stage for testing in human clinical trials.
Journal ArticleDOI
Pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in mice
Siddhartha Mukherjee,Noopur Raje,Jesse Schoonmaker,Julie C. Liu,Teru Hideshima,Marc N. Wein,Dallas C. Jones,Sonia Vallet,Mary L. Bouxsein,Samantha Pozzi,Shweta Chhetri,Y. David Seo,Joshua P. Aronson,Chirayu G. Patel,Mariateresa Fulciniti,Louise E. Purton,Laurie H. Glimcher,Jane B. Lian,Gary S. Stein,Kenneth C. Anderson,David T. Scadden +20 more
TL;DR: It is shown that a tissue-resident adult stem cell population in vivo can be pharmacologically modified to promote a regenerative function in adult animals.
Journal ArticleDOI
The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo.
Hiroshi Ikeda,Teru Hideshima,Mariateresa Fulciniti,Robert J. Lutz,Hiroshi Yasui,Yutaka Okawa,Tanyel Kiziltepe,Sonia Vallet,Samantha Pozzi,Loredana Santo,Giulia Perrone,Yu-Tzu Tai,Diana Cirstea,Noopur Raje,Christoph Uherek,Benjamin Dälken,Silke Aigner,Frank Osterroth,Nikhil C. Munshi,Paul G. Richardson,Kenneth C. Anderson +20 more
TL;DR: The results provide the preclinical framework supporting evaluation of nBT062-maytansinoid derivatives in clinical trials to improve patient outcome in MM.
Journal ArticleDOI
5-Azacytidine, a DNA methyltransferase inhibitor, induces ATR-mediated DNA double-strand break responses, apoptosis, and synergistic cytotoxicity with doxorubicin and bortezomib against multiple myeloma cells
Tanyel Kiziltepe,Teru Hideshima,Laurence Catley,Noopur Raje,Hiroshi Yasui,Norihiko Shiraishi,Yutaka Okawa,Hiroshi Ikeda,Sonia Vallet,Samantha Pozzi,Kenji Ishitsuka,Enrique M. Ocio,Dharminder Chauhan,Kenneth C. Anderson +13 more
TL;DR: 5-azacytidine overcame the survival and growth advantages conferred by exogenous interleukin-6 (IL-6), insulin-like growth factor-I (IGF-I), or by adherence of MM cells to BMSCs, and these data provide the preclinical rationale for the clinical evaluation of 5-azACYtidine, alone and in combination with doxorubicin and bortezomib, to improve patient outcome.